Publications by authors named "Anna Allemann"
Article Synopsis
- A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
- Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
- The treatment was generally well-t
Mesenchymal chondrosarcoma is a rare and aggressive sarcoma subtype with high risk for distant metastases and poor prognosis. Currently NCCN- and ESMO-Guidelines recommend using Ewing sarcoma protocols as standard treatment. Nevertheless, in localized disease overall 5-year survival rates are below 50% whereas in metastatic spread median progression-free survival rates of only 5 months can be expected.
View Article and Find Full Text PDF